Of the 7 prostatic carcinomas with missense mutations, small insertions/deletions and copy number changes in TP53, TMPRSS2-ERG fusion was seen in 4 cases, PTEN mutations/ copy number loss in 3 and AR amplification in 1. This evidence concerns the gene AR and prostate carcinoma.